Critical Review: AZURRX BIOPHARM (AZRX) & Teva Pharmaceutical Industries Limited (NYSE:TEVA)

[ad_1]

AZURRX BIOPHARM (NASDAQ: AZRX) and Teva Pharmaceutical Industries Limited (NYSE:TEVA) are each medical corporations, however which is the higher enterprise? We will evaluate the 2 corporations based mostly on the energy of their threat, valuation, institutional possession, earnings, badyst suggestions, dividends and profitability.

Valuation & Earnings

This desk compares AZURRX BIOPHARM and Teva Pharmaceutical Industries Limited’s top-line income, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
AZURRX BIOPHARM N/A N/A -$14.59 million N/A N/A
Teva Pharmaceutical Industries Limited $21.90 billion zero.64 $329.00 million ($5.95) -2.33

Teva Pharmaceutical Industries Limited has increased income and earnings than AZURRX BIOPHARM.

Dividends

Teva Pharmaceutical Industries Limited pays an annual dividend of $zero.94 per share and has a dividend yield of 6.eight%. AZURRX BIOPHARM doesn’t pay a dividend. Teva Pharmaceutical Industries Limited pays out -15.eight% of its earnings within the type of a dividend.

Analyst Recommendations

This is a abstract of present scores and goal costs for AZURRX BIOPHARM and Teva Pharmaceutical Industries Limited, as supplied by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AZURRX BIOPHARM zero zero 2 zero three.00
Teva Pharmaceutical Industries Limited 5 15 6 zero 2.04

AZURRX BIOPHARM presently has a consensus worth goal of $7.50, suggesting a possible upside of 157.73%. Teva Pharmaceutical Industries Limited has a consensus worth goal of $21.47, suggesting a possible upside of 55.12%. Given AZURRX BIOPHARM’s stronger consensus score and increased doable upside, badysts plainly consider AZURRX BIOPHARM is extra favorable than Teva Pharmaceutical Industries Limited.

Profitability

This desk compares AZURRX BIOPHARM and Teva Pharmaceutical Industries Limited’s internet margins, return on fairness and return on belongings.

Net Margins Return on Equity Return on Assets
AZURRX BIOPHARM N/A -470.72% -205.35%
Teva Pharmaceutical Industries Limited -24.35% 15.70% 5.12%

Institutional & Insider Ownership

6.zero% of AZURRX BIOPHARM shares are held by institutional traders. Comparatively, 55.eight% of Teva Pharmaceutical Industries Limited shares are held by institutional traders. 9.1% of AZURRX BIOPHARM shares are held by firm insiders. Comparatively, 7.1% of Teva Pharmaceutical Industries Limited shares are held by firm insiders. Strong institutional possession is a sign that hedge funds, endowments and huge cash managers consider a inventory will outperform the market over the long run.

Summary

Teva Pharmaceutical Industries Limited beats AZURRX BIOPHARM on eight of the 12 components in contrast between the 2 shares.

AZURRX BIOPHARM Company Profile

AZURRX BIOPHARM logoAzurRx BioPharma, Inc. is a medical development-stage biopharmaceutical firm. The Company is engaged within the badysis and growth of non-systemic biologics for the remedy of sufferers with gastrointestinal (GI) issues. The Company’s product pipeline consists of two therapeutic proteins, corresponding to MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, referred to as LIP2, that the Company is growing via recombinant deoxyribonucleic acid (DNA) know-how for the remedy of exocrine pancreatic insufficiency (EPI), related to persistent pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase mixture of bacterial origin below growth for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (referred to as nosocomial infections), in addition to the prevention of antibiotic-badociated diarrhea (AAD).

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited logoTeva Pharmaceutical Industries Limited is a pharmaceutical firm. The Company is engaged in growing, producing and advertising generic medicines and a portfolio of specialty medicines. The Company operates via two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a spread of dosage types, together with tablets, capsules, injectables, inhalants, liquids, ointments and lotions. Its specialty medicines enterprise focuses on delivering a spread of options to sufferers and suppliers via medicines, gadgets and providers in varied areas and markets all over the world. Its specialty medicines enterprise contains its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a give attention to bronchial asthma and persistent obstructive pulmonary illness. It additionally has specialty merchandise in oncology, ladies’s well being and chosen different areas.




Receive News & Ratings for AZURRX BIOPHARM Daily – Enter your e mail tackle under to obtain a concise every day abstract of the most recent information and badysts’ scores for AZURRX BIOPHARM and badociated corporations with MarketBeat.com’s FREE every day e mail e-newsletter.

[ad_2]
Source hyperlink

Leave a Reply

Your email address will not be published.